Here are the Form 4 insider transactions from Maze Therapeutics, Inc. (MAZE) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow MAZE and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full MAZE filings page.
Maze Therapeutics President, R&D & CMO Harold Bernstein reported an automatic stock transaction under a Rule 10b5-1 trading plan. On February 2, 2026, he exercised a stock option for 15,000 shares of common stock at an exercise price of $10.42 per share.
On the same date, he sold a total of 15,000 common shares in several market transactions at weighted average prices of $44.205, $45.8891, $46.3732 and $47.23 per share, with actual sale prices ranging from $44.15 to $47.17 per share. After these sales, he reported 0 shares of common stock directly owned and 297,407 stock options remaining, linked to an award that began vesting on October 3, 2023.
Maze Therapeutics SVP Finance Amy Bachrodt reported option exercises and share sales. On February 2, 2026, she exercised stock options for 4,844 and 156 shares of common stock at an exercise price of $10.42 per share.
That same day she sold 200 shares at $44.15, 4,064 shares at a weighted average price of $46.0305, and 736 shares at a weighted average price of $46.6323. The sales were effected under a Rule 10b5-1 trading plan. After these transactions, she directly owned 12,965 common shares, along with vested and vesting stock options.
Maze Therapeutics, Inc. executive Atul Dandekar reported an option exercise and planned share sales. On January 29, 2026, he exercised a stock option for 7,500 shares of common stock at $10.42 per share, from a fully vested award. The same day, he sold 7,500 common shares in three trades: 1,200 shares at $43.1844, 3,500 shares at $44.0419, and 2,800 shares at $45.008, all under a pre-established Rule 10b5-1 trading plan. After these transactions, he reported owning 10,503 shares of common stock and 66,643 stock options, all held directly.
Maze Therapeutics SVP of Finance Amy Bachrodt reported option exercises and a stock sale. On January 22, 2026, she exercised stock options to acquire 2,497 and 2,503 shares of common stock at an exercise price of $10.42 per share. On the same date, she sold 5,000 shares of common stock at a weighted average price of $45.5224 per share under a pre-arranged Rule 10b5-1 trading plan. Following these transactions, she directly held 12,965 shares of Maze Therapeutics common stock and retained stock options covering 486 and 7,869 shares, subject to monthly vesting schedules.
Maze Therapeutics executive Harold Bernstein, President, R&D & CMO, reported an option exercise and related share sale. On January 7, 2026, he exercised a stock option for 25,156 shares of common stock at an exercise price of $10.42 per share, converting a previously held derivative position into common stock.
On the same day, he sold the same 25,156 shares of common stock at a weighted average price of $40.2011 per share under a Rule 10b5-1 trading plan adopted on September 29, 2025, leaving him with 0 directly held common shares and 312,407 stock options outstanding. The sale price reflects multiple transactions between $40.00 and $40.55 per share.
Maze Therapeutics director Catherine A. Sohn reported a series of stock option exercises and related common share sales. On January 6, 2026, she exercised 2,493 stock options at an exercise price of $10.42 per share and sold 2,493 common shares at a weighted average price of $38.616 per share, leaving no common shares directly owned.
On January 7, 2026, she exercised additional options for 20,744, 2,895, and 3,281 common shares at an exercise price of $10.42 per share and then sold 26,920 common shares at a weighted average price of $39.1079 per share, again ending with 0 common shares directly held. Following these transactions, she continues to hold stock options, including 3,211, 316, and 5,805 derivative securities with expiration dates between 2031 and 2034.
Maze Therapeutics, Inc. officer Harold Bernstein reported option exercises and share sales. On January 2, 2026, he exercised stock options to acquire 4,432 shares of common stock at $10.42 per share and sold 4,432 shares of common stock at a weighted average price of $40.4304 per share under a Rule 10b5-1 trading plan adopted on September 29, 2025. On January 5, 2026, he exercised options to acquire an additional 412 shares at $10.42 and sold 412 shares at $40.00 per share. Following these transactions, he continued to hold stock options, including 337,563 option shares directly owned, which vest over time according to a set schedule.
Maze Therapeutics SVP of Finance Amy Bachrodt reported option exercises and share sales in company stock. On January 2, 2026, she exercised stock options for 204 and 4,796 shares of common stock at an exercise price of $10.42 per share. These options relate to grants that vest monthly and one award that was fully vested as of March 1, 2025.
On the same date, she sold 2,405 shares at a weighted average price of $38.6995 and 2,595 shares at a weighted average price of $39.5689, in multiple trades within stated price ranges. After these transactions, she directly held 12,965 shares of common stock and 2,377 and 2,983 stock options. All trades were executed under a Rule 10b5-1 trading plan adopted on September 29, 2025.
Maze Therapeutics, Inc. director reports receipt of common stock through fund distribution. A Maze Therapeutics, Inc. (MAZE) director reported acquiring 1,489 shares of common stock on 11/19/2025 at a price of $0 per share, described as his pro rata share of a distribution from entities affiliated with Third Rock Ventures made for no consideration under an Exchange Act exemption. Following this transaction, he beneficially owns 31,113 shares directly and 7,422 shares indirectly through the Charles J. Homcy Revocable Trust UA 11/4/1998, for which he serves as trustee. This is a routine ownership reporting update rather than a new open-market purchase or sale.